Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.72 |
| ▸ | HTR1A | P08908 | 9/20 | 0.72 |
| ▸ | DRD1 | P21728 | 3/20 | 0.62 |
| ▸ | HTR2A | P28223 | 3/20 | 0.60 |
| ▸ | HTR7 | P34969 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10640578 | 0.86 | DRD2 (0.61) | DRD2HTR1ADRD1HTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL10636899 | 0.85 | DRD2 (0.60) | DRD2HTR1ADRD1HTR2AHTR7 | |
| SCHEMBL59765 | 0.84 | DRD2 (1.00) | DRD2HTR1ADRD1HTR2AHTR7 | |
| SCHEMBL31029854 | 0.84 | DRD2 (1.00) | DRD2HTR1ADRD1HTR2AHTR7 | |
| SCHEMBL29723260 | 0.84 | DRD2 (1.00) | DRD2HTR1ADRD1HTR2AHTR7 | |
| SCHEMBL25173335 | 0.84 | DRD2 (1.00) | DRD2HTR1ADRD1HTR2AHTR7 | |
| SCHEMBL31079473 | 0.84 | DRD2 (1.00) | DRD2HTR1ADRD1HTR2AHTR7 | |
| Bromide SCHEMBL11710282 | 0.83 | DRD2 (0.97) | DRD2HTR1ADRD1HTR2AHTR7 | |
| SCHEMBL28809991 | 0.83 | DRD2 (0.97) | DRD2HTR1ADRD1HTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL11707353 | 0.83 | DRD2 (0.97) | DRD2HTR1ADRD1HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020147848-A1 | TRICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-07-23 | — | — | WO | disclosed |
| EP-2938341-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9884844-B2 | Heterocyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884844-B2 | Heterocyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884844-B2 | Heterocyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| EP-2938341-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| WO-2014106238-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FANG, QUN, KEVIN (US) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014106238-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FANG, QUN, KEVIN (US) | 2014-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | GRIN2C, COMT, NLN | DRD2 281/4885HTR1A 217/4885DRD1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.